Firstkind team

The geko™ device and OnPulse™ technology, when first brought to market, were focussed on the prevention of DVT, where there was an obvious opportunity to make a real difference for a large number of people. The product development team at Firstkind have since expanded this shared vision and created the process under which the formative concept of neuromuscular stimulation for DVT prevention has now been extended to the prevention and treatment of oedema arising from injury, immobility e.g. following surgery, the promotion of wound healing and the treatment of venous insufficiency and ischemia.




    Ron Long


    Chairman Ron has brought over 30 novel life science and healthcare technologies from research to market. Ron was formerly Commercial Director within Amersham International plc; CEO of Amersham Pharmacia Biotech then appointed Vice Chairman of the Amersham Group until his retirement from Amersham in 2001. Prior to joining Amersham, Ron worked for 22 years with the Wellcome Foundation Plc, holding Divisional and Managing Director appointments before leaving in 1990 to join Amersham. Since leaving Amersham Ron has served as Chairman of several start-up companies including Kudos Pharmaceuticals which was acquired by Astra Zeneca and DxS which was acquired by Qiagen.


    Bernard Ross

    Chief Executive Officer

    Bernard has over 15 years of senior experience at private & public board level across multiple industries including pharmaceutical, technology development and FMCG. A former Head of International Development at CMI plc, Senior Vice President, Cardiovascular of Bioaccelerate Inc. (BACL), CEO Innacardio Inc


    Andrew Thelwell

    Chief Commercial Officer

    Andrew has 29 years' experience within medical devices and biotechnology, across a broad range of sales, marketing and commercial roles. Within the biotech area his most recent role was Director of European Commercial Operations, but the bulk of his career has been spent in medical devices, initially at Smith and Nephew and then with ConvaTec where roles included General Manager UK, Ireland and Benelux; and Global Franchise Director for wound care. 


    Rachel Fallon

    Chief Technology Officer

    Rachel brings over 20 years' experience working in the life science business. She previously held senior roles including Science Director and R&D Director in Amersham Biosciences bringing to bear her broad experience of technology development in proteomics and genomics reagents and instrumentation. Most recently, Rachel was Director of Sense Proteomics, now part of the OGT Group focussing on new approaches to Molecular Medicine. Here she directed the discovery of novel diagnostic markers for cancer and autoimmune disease. 


    Francis Cooper

    Chief Financial Officer

    Francis is a Chartered Accountant and MBA with 30 years experience in finance and accountancy  across a broad spectrum of industries and business stages, including start-ups, turnaround and high growth companies from SMEs to multinationals.  He has had 8 years experience in the MedTech industry focused on medical devices.